Policy paper

Voluntary scheme for branded medicines pricing and access

An agreement between DHSC and the Association of the British Pharmaceutical Industry (ABPI), on getting the best value and most effective medicines into use more quickly.

Documents

The 2019 voluntary scheme for branded medicines pricing and access: annexes

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk . Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The voluntary scheme for branded medicines pricing and access is a non-contractual voluntary agreement between the Department of Health and Social Care (DHSC) and the Association of the British Pharmaceutical Industry (ABPI).

DHSC is acting on behalf of the UK government, representing the governments of Scotland, Wales and Northern Ireland. The ABPI is the representative body of the UK pharmaceutical industry.

The voluntary scheme aims to:

  • improve patient access to medicines by getting the best value and most effective medicines into use more quickly
  • keep the branded medicine bill affordable for the NHS through a cap in growth of branded sales
  • support innovation and a successful life sciences industry in the UK

The voluntary scheme will start on 1 January 2019 and will be in place for 5 years until 2023.

The annexes document may not be compatible with assistive technology for viewing documents. To request a fully accessible version, contact dh.brandedmedicines@dhsc.gov.uk.

Published 5 December 2018